A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer

Trial Profile

A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Avelumab (Primary)
  • Indications Gastric cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms JAVELIN Solid Tumor Japan
  • Sponsors Merck KGaA; Merck Serono
  • Most Recent Events

    • 19 Jun 2017 Planned End Date changed from 1 May 2017 to 28 Dec 2018.
    • 24 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 May 2017 as reported by ClinicalTrials.gov.
    • 24 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top